Heather Bresch

  • Title
    CEO
  • Affiliation
    Mylan
  • Age
    46
Bresch has overseen a lot of drama at generic-drug maker Mylan in her nearly four years as CEO. After acquiring part of Abbott Laboratories earlier this year, Bresch moved the $7.7 billion Mylan to the Netherlands in a controversial “tax inversion” play, then thwarted a plan from Israel-based Teva to buy Mylan for $40 billion. Now Bresch is trying her own hostile takeover of Ireland-based Perrigo.

Read more about Heather Bresch in “Why Wall Street loves to hate Mylan's CEO.”

Personal Information

2020 Rank31
Newcomer?NO

Company Financials

Revenues ($M)7,720
Profits ($M)929
Market Value as of 09/18/18 ($M)23,737